ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1087

Kidney Medullary Oxygen Availability Is Higher in CKD: Truth or Fallacy?

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms

Authors

  • Prasad, Pottumarthi V., NorthShore University HealthSystem, Evanston, Illinois, United States
  • Li, Luping, NorthShore University HealthSystem, Evanston, Illinois, United States
  • Hack, Bradley K., NorthShore University HealthSystem, Evanston, Illinois, United States
  • Leloudas, Nondas, NorthShore University HealthSystem, Evanston, Illinois, United States
  • Sprague, Stuart M., NorthShore University HealthSystem, Evanston, Illinois, United States
Background

Chronic hypoxia hypothesis (CHH) suggests kidneys with progressive CKD are hypoxic. Currently Blood Oxygenation Level Dependent (BOLD) MRI is the only known technique to afford evaluation of kidney oxygen status in humans. Results to-date show higher R2* (i.e. lower O2 availability) in cortex but lower R2* in medulla (suggesting higher O2 availability) in CKD compared to controls. Whether the lower R2* in medulla in CKD an anomaly remains untested. Hypothesizing that reduced fractional blood volume (fBV) within tissue is the cause for this anomaly [PMID: 29571450], we measured fBV in CKD using ferumoxytol, an intravascular MRI contrast agent.

Methods

Data was available in 9 each in controls and individuals with CKD. After baseline R2* maps were acquired, ferumoxytol (5mg/kg) was administered and R2* measurement repeated. fBV, and oxygen saturation of hemoglobin (StO2) were calculated using equations described previously for brain MRI [31482602].

Results

Table 1 summarizes the R2*, fBV, StO2 and bloodPO2 for cortex and medulla. Consistent with prior reports, R2* in medulla is significantly lower in CKD implying higher O2 availability in CKD. However, when including the fact that fBV is lower in CKD, estimated StO2 and bloodPO2 are significantly lower in medulla.

Conclusion

Our data for the first time demonstrate that fBV is significantly lower in CKD in both cortex and medulla. When including this lower fBV, cortex and medulla are both moderately hypoxemic in CKD while in controls, cortex was normoxemic and medulla mildly hypoxemic. The blood pO2 estimates are consistent with the only report to-date in rat kidneys [16357065].

Funding

  • NIDDK Support – Covis Pharma (providing drug)